Previous 10 | Next 10 |
Guardant Health, Inc. (GH) Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - ...
The following slide deck was published by Guardant Health, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Guardant Health, Inc. 2022 Q2 - Results - Earnings Call Presentation
Guardant Health press release ( NASDAQ: GH ): Q2 Non-GAAP EPS of -$1.00 misses by $0.03 . Revenue of $109.1M (+18.5% Y/Y) beats by $3.96M . Guardant Health continues to expect full year 2022 revenue to be in the range of $460 million to $470 million vs. $465.73...
Q2 clinical and biopharma volumes up 40% and 65% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported fin...
The shares of cancer test maker Guardant Health ( NASDAQ: GH ) recovered from two consecutive days of losses on Tuesday after the company announced it received Medicare coverage for the Guardant Reveal molecular residual disease (MRD) test. The decision of Palmetto GBA, a ...
First blood-only liquid biopsy test for molecular residual disease testing now covered for certain fee-for-service Medicare patients in US with stage II or III colorectal cancer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Pa...
The company recently signed a deal with the premier electronic medical record company, EPIC. Realizing the tremendous value of its business, Guardant acquired all remaining shares from its Joint Venture partner, SoftBank. Launch of the Laboratory Developed Test would further boost...
One key metric that allows us to see under the surface of the market is “relative strength”, or how well a stock is faring against other stocks in the same market space. (1) This method helped William O’Neil become an investing legend (2), and the CANSLIM approach he foun...
GH has a lineup of positive catalysts in place regarding its product pipeline updates, and in fact, has a growing TAM to consider. However, a potential recession may hurt the company's oncology test demand, which may hurt its bottom line and further hurt its shareholders with potentia...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 ...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...